You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Fennec Pharms Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Fennec Pharms Inc
International Patents:36
US Patents:7
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Fennec Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fennec Pharms Inc PEDMARK sodium thiosulfate SOLUTION;INTRAVENOUS 212937-001 Sep 20, 2022 RX Yes Yes 11,510,984 ⤷  Subscribe Y ⤷  Subscribe
Fennec Pharms Inc PEDMARK sodium thiosulfate SOLUTION;INTRAVENOUS 212937-001 Sep 20, 2022 RX Yes Yes 11,992,530 ⤷  Subscribe ⤷  Subscribe
Fennec Pharms Inc PEDMARK sodium thiosulfate SOLUTION;INTRAVENOUS 212937-001 Sep 20, 2022 RX Yes Yes 11,964,018 ⤷  Subscribe ⤷  Subscribe
Fennec Pharms Inc PEDMARK sodium thiosulfate SOLUTION;INTRAVENOUS 212937-001 Sep 20, 2022 RX Yes Yes 11,998,604 ⤷  Subscribe ⤷  Subscribe
Fennec Pharms Inc PEDMARK sodium thiosulfate SOLUTION;INTRAVENOUS 212937-001 Sep 20, 2022 RX Yes Yes 11,617,793 ⤷  Subscribe Y ⤷  Subscribe
Fennec Pharms Inc PEDMARK sodium thiosulfate SOLUTION;INTRAVENOUS 212937-001 Sep 20, 2022 RX Yes Yes 11,291,728 ⤷  Subscribe Y ⤷  Subscribe
Fennec Pharms Inc PEDMARK sodium thiosulfate SOLUTION;INTRAVENOUS 212937-001 Sep 20, 2022 RX Yes Yes ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Fennec Pharms Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0290047 SPC/GB97/078 United Kingdom ⤷  Subscribe PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
2203431 15C0013 France ⤷  Subscribe PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119
0480717 98C0022 France ⤷  Subscribe PRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825
1499331 SPC/GB13/034 United Kingdom ⤷  Subscribe PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313
0579826 SPC/GB02/042 United Kingdom ⤷  Subscribe PRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020422
1175904 2007C/048 Belgium ⤷  Subscribe PRODUCT NAME: ALENDRONATE DE SODIUM/COLECALCIFEROL; AUTHORISATION NUMBER AND DATE: EU/1/05/310/001 20050826
2203431 2015/009 Ireland ⤷  Subscribe PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REGISTRATION NO/DATE: EU/1/14/983 20150115
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.